



SENATE BILL 871: Right To Try Individualized Treatments.

2023-2024 General Assembly

Committee:	Senate Health Care. If favorable, re-refer to Judiciary. If favorable, re-refer to Appropriations/Base Budget. If favorable, re-refer to Rules and Operations of the Senate	Date:	May 22, 2024
Introduced by:	Sen. Sawrey	Prepared by:	Theresa Matula
Analysis of:	First Edition		Legislative Analyst

OVERVIEW: *Senate Bill 871 would allow eligible patients with life-threatening or severely debilitating illnesses the right to try individualized investigational drugs, biological products, and devices. This portion of the bill would become effective October 1, 2024.*

The bill also appropriates \$50,000 to the Department of Health and Human Services for the 2024-2025 fiscal year for implementation. The appropriation section of the bill would become effective July 1, 2024.

[As introduced, this bill was identical to H1029, as introduced by Reps. Chesser, Blackwell, Potts, Reeder, which is currently in House Health.]

CURRENT LAW: S.L. 2015-137 (HB 652) created Article 23A (Right to Try Act), Chapter 90 of the General Statutes, which established a process for terminally ill eligible patients to obtain access to investigational drugs, biological products, and devices when various criteria are met.

S.L. 2019-70 (HB 934) labeled the initial language from S.L. 2015-137 as "Part 1. Experimental Treatments" and created "Part 2. Investigational Adult Stem Cell Treatments" to authorize access to and use of investigational adult stem cell treatments for patients with certain severe chronic diseases.

BILL ANALYSIS: Section 1 of Senate Bill 871 would create "Part 3. Individualized Treatments" under Article 23A of Chapter 90 of the General Statutes to allow an eligible patient access to an individualized investigational drug, biological product, or device.

The bill contains the elements outlined below.

- Creates a definitions section (G.S. 90-325.30) containing definitions for: "eligible facility;" "eligible patient;" "individualized investigational drug, biological product, or device;" "institution;" "life-threatening or severely debilitating illness;" and "written, informed consent." Information on select definitions is provided below.
 - *Eligible facility* – An institution operating under Federalwide Assurance for the Protection of Human Subjects, in accordance with 45 C.F.R § 46 and 42 U.S.C. §289(a).
 - *Eligible patient* – Must meet all of the following criteria: an individual with a physician-attested life-threatening or severely debilitating illness; has considered all FDA treatment options in consultation with a treating physician; received a recommendation from the treating physician for use of the individualized investigational drug, biological product, or

Jeffrey Hudson
Director



Legislative Analysis
Division
919-733-2578

Senate Bill 871

Page 2

device; has given informed consent in writing; and has documentation from the treating physician that the individual meets all of the criteria.

- *Individualized investigational drug, biological product, or device* - A drug, biological product, or device that is unique and produced exclusively for an individual patient based on their own genetic profile, including individualized gene therapy antisense oligonucleotides and individualized neoantigen vaccines.
- *Life-threatening or severely debilitation illness* – As the term is defined in 21 C.F.R. §312.81. Life-threatening means: "(1) Diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted; and (2) Diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival." Severely debilitating means "diseases or conditions that cause major irreversible morbidity."
- Authorizes access to and use of individualized investigational drugs, biological products, or devices by providing that a manufacturer operating within an eligible facility and in accordance with federal law, may make, but is not required to make, the manufacturer's product available to an eligible patient with or without compensation. (G.S. 90-325.31)
- Prohibits liability for the eligible patient's heirs for outstanding debt related to the use of the individualized investigational drug, biological product, or device if the eligible patient dies while being treated. (G.S. 90-325.32)
- Prohibits sanctions (revocation, failure to renew, suspension, or other disciplinary action) against a health care provider based solely on the provider's recommendation to an eligible patient related to the individualized investigational drug, biological product, or device. (G.S. 90-325.33)
- Prohibits an official, employee, or agent of the State from blocking access to an individualized investigational drug, biological product, or device. However, counseling, advice, or recommendations consistent with medical standards of care from a licensed health care provider is not a violation. (G.S. 90-325.34)
- Prohibits a private right of action against manufacturers of individualized investigational drugs, biological products, or devices resulting from use, if the manufacturer, person, or entity made a good-faith effort to comply with the provisions of this Part and exercised reasonable care. (G.S. 90-325.35)
- A health benefit plan is not required to cover an insured's participation in a clinical trial. (G.S. 90-325.26)

Section 2 of the bill appropriates \$50,000 from the General Fund to the Department of Health and Human Services, for the 2024-2025 fiscal year to implement the act.

EFFECTIVE DATE: The right to try portion of the bill would become effective October 1, 2024, the appropriation section would become effective July 1, 2024, and the remainder would become effective when it becomes law.